
News|Articles|December 1, 2006
FDA Actions in Brief (December 2006)
Imatinib (Gleevec, Novartis) was approved for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
2
What IRA drug prices will mean for PBMs, health plans and patients
3
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
4
Biosimilars in 2025: A year of firsts
5





















































